159989-65-8

Usage

Uses

Used in Pharmaceutical Industry:
Nelfinavir mesylate is used as an antiviral agent for the treatment of HIV. It functions as an HIV protease inhibitor, blocking the processing of gag and gag-pol polyproteins required for viral maturation. This leads to a significant reduction in viral load and an improvement in CD4 counts, making it an essential component in the fight against HIV.
Additionally, Nelfinavir mesylate exhibits some anticancer properties, although its specific applications in this field are not detailed in the provided materials.
Used in COVID-19 Research:
Nelfinavir mesylate is also a COVID-19-related research product, indicating its potential use in the study and treatment of the novel coronavirus. While the specific application in this context is not provided, its status as a research product suggests that it may be investigated for its effectiveness against the virus or for its potential to contribute to the development of new treatments.

Originator

Agouron (US)

Biological Activity

Orally active human immunodeficiency virus protease inhibitor. Potently inhibits HIV-1 protease (K i = 2 nM) in vitro .

Biochem/physiol Actions

Nelfinavir mesylate hydrate, also known as AG1343, is used as a therapeutic agent for acquired immunodeficiency syndrome (AIDS). It acts as an antifibrotic agent and is used to treat pulmonary fibrosis in patients with systemic sclerosis (SSc). In addition, nelfinavir mesylate hydrate reduces inflammation by activating protein phosphatase 2 (PP-2) and blocking mitogen-activated protein kinases (MAPK) signaling in macrophages. It also stimulate autophagy and exhibit anti-cancer property.

References

1) Olmo?et al.?(2006),?A review of nelfinavir for the treatment of HIV infection; Expert Opin. Drug Metab. Toxicol.,?2?285 2) Bruning?et al.?(2010),?New prospects for nelfinavir in non-HIV-related diseases; Curr. Mol. Pharmacol.,?3?91 3) Gills?et al.?(2007),?Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo; Clin. Cancer Res,?13?5183 4) Shim?et al. (2012),?Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir; J. Natl. Cancer Inst,,?104?1576

InChI:InChI=1/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1

Upstream product

• 75-75-2 methanesulfonic acid 
• 159989-64-7 nelfinavir 
• 201402-98-4 (2R,3R)-4-((3S,4aS,8aS)-3-(tertbutylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(phenylthio)butan-2-aminium benzoate 
• 201402-97-3 2-{(S)-4-[(R)-2-((3S,4aS,8aS)-3-tert-Butylcarbamoyl-octahydro-isoquinolin-2-yl)-1-hydroxy-ethyl]-4,5-dihydro-oxazol-2-yl}-benzoic acid methyl ester 
• 67000-01-5 methyltertbutyl ether 

Relevant academic research and scientific papers

Optimization of an electrolyte system for the simultaneous separation of nelfinavir mesylate and two impurities by micellar electrokinetic chromatography

A methodology for the simultaneous determination of nelfinavir mesylate and the impurities 3-hydroxy-2-methylbenzoic acid and (2R,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl) octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(phenylthio)butan-2-aminium benzoate by micellar electrokinetic chromatography, with an analysis time of 25 min, was proposed. An electrolyte composed of sodium tetraborate buffer (pH 9.24; 25 mmol L-1), sodium dodecyl sulphate (9 mmol L-1) and methanol (10percent, v/v) was optimized using a mixed-level factorial design, with direct detection at 200 nm. After evaluating some figures of merit, such as selectivity, linearity, precision, limit of detection, limit of quantification, accuracy and robustness (using Youden's test), the method was successfully applied to the analysis of nelfinavir mesylate and its impurities in a pharmaceutical formulation. The optimized methodology is demonstrated to be useful in the determination of these analytes in a synthesis monitoring process, in raw materials and in pharmaceutical formulations, while offering low solvent consumption, requiring a small sample and using non-specific columns as advantages.

AN IMPROVED PROCESS FOR PREPARATION OF AMORPHOUS NELFINAVIR MESYLATE

The invention relates to a new improved process to prepare amorphous form of [2S-(3R*, 4aR*, 8aR*, 2'S*, 3'S*)]-2'-[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-(2'methyl-3'-hydroxyphenyl)pentyl]decahydroisoquinoline-3-N-tert-butylcarboxamide methanesulfonate

NOVEL CRYSTALLINE FORMS OF NELFINAVIR MESYLATE

The present invention provides novel crystalline forms of Nelfinavir mesylate, Form-A, Form-B, Form-C, Form-D and the process for their preparation without the use of any special equipment such as a spray drier, avoiding the use of highly flammable solven

Method of making a HIV-Protease inhibitor

The present invention is directed to a method of making the HIV-protease inhibitor nelfinavir mesylate.

Production of amide derivatives and intermediate compounds therefor

A method for producing an amide derivative of the formula ?XV! STR1 wherein each symbol is as defined in the specification, and an enantiomer thereof, a novel intermediate useful for producing said compound and a production method thereof. The production method of the present invention is extremely easy and simple as compared to the conventional methods, and enables effective production of compound ?XV! at high yields, which includes compound ?XVI! having an HIV protease inhibitory action. In addition, the novel intermediates of the present invention are extremely useful as intermediates for producing not only the aforementioned compound ?XVI! but also compounds useful as X-ray contrast media.